发现新的莱纳利多米德衍生物作为强效和选择性的GSPT1降解剂
Yiying Wei1, Xinxin Xu1, Minchuan Jiang1
1International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Development, Ministry of Education (MoE) of the People's Republic of China, College of Pharmacy, Jinan University, 601 Huangpu Avenue West, Guangzhou, 510632, China.
European journal of medicinal chemistry
|July 7, 2023
概括
研究人员开发了一种新型化合物9q,该化合物有效降解GSPT1 (G1到S相过渡1),这是癌症发展的关键因素. 这种有针对性的方法通过抑制癌细胞增殖,显示出新的癌症治疗方法的前景.
科学领域:
- 分子生物学分子生物学
- 在瘤学瘤学.
- 药物发现 药物发现 药物发现
背景情况:
- G1到S阶段过渡1 (GSPT1) 对于翻译终结至关重要,并且在各种癌症中起着瘤原因驱动的作用.
- GSPT1是一个有前途的治疗标,但现有的选择性降解剂尚未获得临床批准.
- 开发新的,有效的GSPT1降解剂对于推进癌症治疗策略至关重要.
研究的目的:
- 设计和合成针对GSPT1.1的新型选择性降解剂.
- 为了评估化合物的疗效和作用机制,9q.
- 评估化合物9q在相关癌症细胞系中的抗癌潜力.
主要方法:
- 新型GSPT1降解剂的合成和选.
- 通过蛋白质分子分析来确定降解效率 (DC50) 和选择性.
- 通过ubiquitin-proteasome系统对降解途径的研究.
- 对抗增殖活性 (IC50) 和细胞循环效应 (G0/G1停止,细胞亡) 的评估.
主要成果:
- 化合物9q在U937细胞中表现出强大的GSPT1降解 (DC50 = 35nM),具有良好的选择性.
- 机制研究证实,9q通过ubiquitin-proteasome途径诱导GSPT1降解.
- 化合物9q对U937,MOLT-4和MV4-11癌细胞系表现出显著的抗增殖作用 (纳米分子范围内的IC50值).
- 9q诱导了U937细胞的剂量依赖G0/G1阶段停止和亡.
结论:
- 化合物9q是一种高效和选择性的GSPT1降解剂.
- 无素-蛋白酶体系统介导由9q诱导的GSPT1降解.
- 化合物9q通过抑制增殖和诱导细胞死亡,显示出作为抗癌治疗剂的显著潜力.
相关概念视频
Glucagon-like Receptor Agonists
365
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
365
Drug Discovery: Overview
8.1K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
8.1K
Dipeptidyl Peptidase 4 Inhibitors
214
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
214
Drugs that Destabilize Microtubules
2.0K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
2.0K


